Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysis. Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysis

Patients with metastatic urothelial cancer were treated with atezolizumab. Their tumors and matched normal blood were sequenced.